Scholar Rock Hits 3-Year High on Rival Biohaven's Drug Setback
Scholar Rock Hits 3-Year High on Rival Biohaven's Drug Setback
SRRK shares surged over 360% on Oct. 7 after apitegromab met the main goal of a late-stage trial; shares have doubled YTD.Drugmaker $Scholar Rock (SRRK.US)$'s shares were trading more than 33% higher just past 11:55 am ET Monday at $40.04.
製藥商 $Scholar Rock (SRRK.US)$美國東部時間週一上午11點55分過後，其股價上漲了33％以上，至40.04美元。
The company's rival $Biohaven (BHVN.US)$ said on Monday its experimental treatment for a rare neuromuscular disorder failed to meet the main goal of improving patients' motor function in a late-stage trial.
該公司的競爭對手 $Biohaven (BHVN.US)$ 週一表示，在一項後期試驗中，其對一種罕見神經肌肉疾病的實驗治療未能實現改善患者運動功能的主要目標。
Truist analysts raise their peak sales estimate on apitegromab, SRRK's drug for the same disorder, called spinal muscular atrophy, to $1.5 bln from $1.2 bln after Biohaven's announcement, reported Reuters.
路透社報道，Truist分析師將SRRK治療相同疾病（稱爲脊髓性肌萎縮症）的藥物apitegromab的峯值銷售額估計從Biohaven宣佈後的12億美元上調至15億美元。
SRRK shares surged over 360% on Oct. 7 after apitegromab met the main goal of a late-stage trial; shares have doubled YTD.
在apitegromab實現後期試驗的主要目標之後，sRK股價在10月7日飆升了360％以上；股價迄今已翻了一番。
